Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

BACKGROUND: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 on...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8292404/
https://ncbi.nlm.nih.gov/pubmed/33824476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01334-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker